Form 4 for KYMR Kymera Therapeutics, Inc.
Accepted 2026-07-07 20:00:03 ET · period of report 2026-07-07 · accession 0001193125-26-297817 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DT | 2026-07-07 20:00 | 2026-07-07 | KYMR | Mainolfi Nello | CEO, Dir | M - OptEx | $2.08 | +50.0K | 716.6K | +8% | +$104.0K |
| DT | 2026-07-07 20:00 | 2026-07-07 | KYMR | Mainolfi Nello | CEO, Dir | S - Sale+OE | $119.00 | -50.0K | 666.6K | -7% | -$5.95M |
| DMT | 2026-07-07 20:00 | 2026-07-07 | KYMR | Mainolfi Nello | CEO, Dir | M - OptEx | $0.00 | -50.0K | 14.3K | -78% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-07-07 | M | A | 50,000 | $2.08 | 716,568 | D | — | — | (F1) These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 24, 2026 adopted by the reporting person. |
| 2 | Common | Common Stock | 2026-07-07 | S | D | 50,000 | $119.00 | 666,568 | D | — | — | (F1) These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 24, 2026 adopted by the reporting person. |
| 3 | Derivative | Stock Option (Right to Buy) | 2026-07-07 | M | D | 45,559 | $0.00 | 90,000 | D | $2.08 · — to 2029-11-13 | 45,559 Common Stock | (F1) These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 24, 2026 adopted by the reporting person. (F2) The shares underlying this stock option are fully vested and exercisable. |
| 4 | Derivative | Stock Option (Right to Buy) | 2026-07-07 | M | D | 4,441 | $0.00 | 14,284 | D | $2.08 · — to 2029-11-13 | 4,441 Common Stock | (F1) These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 24, 2026 adopted by the reporting person. (F2) The shares underlying this stock option are fully vested and exercisable. |